Kodiak’s VEGF conjugate finally finds footing in diabetic retinopathy

Kodiak’s new Phase III data marks a turnaround for its VEGF program, which had suffered multiple late-stage setbacks before the company discontinued it in mid-2023 and then revived it months later in diabetic retinopathy.

Shares of Kodiak Sciences Inc. (NASDAQ:KOD) rose 43% Thursday to $39.76, their highest level in four years, giving the company a market cap over $2.4 billion, after VEGF antibody biopolymer conjugate Zenkuda tarcocimab tedromer beat sham in the Phase III GLOW2 study in diabetic retinopathy...